Is acute reperfusion therapy safe in acute ischemic stroke patients who harbor unruptured intracranial aneurysm?

2015 ◽  
Vol 10 (SA100) ◽  
pp. 113-118 ◽  
Author(s):  
Ashkan Mowla ◽  
Karanbir Singh ◽  
Sandhya Mehla ◽  
Mohammad K. Ahmed ◽  
Peyman Shirani ◽  
...  
Stroke ◽  
2021 ◽  
Author(s):  
Xuting Zhang ◽  
Shenqiang Yan ◽  
Wansi Zhong ◽  
Yannan Yu ◽  
Min Lou

Background and Purpose: We aimed to investigate the relationship between early NT-proBNP (N-terminal probrain natriuretic peptide) and all-cause death in patients receiving reperfusion therapy, including intravenous thrombolysis and endovascular thrombectomy (EVT). Methods: This study included 1039 acute ischemic stroke patients with early NT-proBNP data at 2 hours after the beginning of alteplase infusion for those with intravenous thrombolysis only or immediately at the end of EVT for those with EVT. We performed natural log transformation for NT-proBNP (Ln(NT-proBNP)). Malignant brain edema was ascertained by using the SITS-MOST (Safe Implementation of Thrombolysis in Stroke-Monitoring Study) criteria. Results: Median serum NT-proBNP level was 349 pg/mL (interquartile range, 89–1250 pg/mL). One hundred twenty-one (11.6%) patients died. Malignant edema was observed in 78 (7.5%) patients. Ln(NT-proBNP) was independently associated with 3-month mortality in patients with intravenous thrombolysis only (odds ratio, 1.465 [95% CI, 1.169–1.836]; P =0.001) and in those receiving EVT (odds ratio, 1.563 [95% CI, 1.139–2.145]; P =0.006). The elevation of Ln(NT-proBNP) was also independently associated with malignant edema in patients with intravenous thrombolysis only (odds ratio, 1.334 [95% CI, 1.020–1.745]; P =0.036), and in those with EVT (odds ratio, 1.455 [95% CI, 1.057–2.003]; P =0.022). Conclusions: An early increase in NT-proBNP levels was related to malignant edema and stroke mortality after reperfusion therapy.


Stroke ◽  
2019 ◽  
Vol 50 (3) ◽  
pp. 652-658 ◽  
Author(s):  
Masaya Enomoto ◽  
Akira Endo ◽  
Hiroshi Yatsushige ◽  
Kiyohide Fushimi ◽  
Yasuhiro Otomo

Stroke ◽  
2021 ◽  
Vol 52 (Suppl_1) ◽  
Author(s):  
Xin Tong ◽  
Sallyann Coleman King ◽  
Erika Odom ◽  
Quanhe Yang

Introduction: Studies suggest a significant reduction in emergency department visits and hospitalizations for acute ischemic stroke (AIS) during the COVID-19 pandemic in the United States. Few studies have examined AIS hospitalizations, treatments, and outcomes during the pandemic period. The present study compared the demographic and clinical characteristics of patients hospitalized with AIS before and during the COVID-19 pandemic (weeks 11-24 in 2019 vs. 2020). Method: We identified 42,371 admissions with a clinical diagnosis of AIS, from 370 participating hospitals who contributed data during weeks 11-24 in both 2019 and 2020 to the Paul Coverdell National Acute Stroke Program (PCNASP). Results: During weeks 11-24 of the COVID-19 period, AIS hospitalizations declined by 24.5% compared to the same period in 2019 (18,233 in 2020 vs. 24,138 in 2019). In 2020, the percentage of individuals aged <65 years who were hospitalized with AIS was higher compared with the same period in 2019 (34.6% vs. 32.7%, p<0.001); arriving by EMS were higher in 2020 compared with 2019 (47.7% vs. 44.8%, p<0.001). Individuals admitted with AIS in 2020 had a higher mean National Institutes of Health Stroke Scale (NIHSS) score compared with 2019 (6.7 vs. 6.3, p<0.001). In 2020, the in-hospital death rates increased by 16% compared to 2019 (5.0% vs. 4.3%, p<0.001). However, there were no differences in rates of alteplase use, achievement of door to needle in 60 minutes, or complications from reperfusion therapy between the two time periods. Conclusion: A higher percentage of younger (<65 years) individuals and more severe AIS cases were admitted to the participating hospitals during weeks 11 to 24 of the COVID-19 pandemic in 2020 compared to the same period in 2019. The AIS in-hospital death rate increased 16% during the pandemic weeks as compared to the same weeks in 2019. Additional studies are needed to examine the impacts of the COVID-19 pandemic on stroke treatment and outcomes.


PLoS ONE ◽  
2016 ◽  
Vol 11 (8) ◽  
pp. e0160502 ◽  
Author(s):  
Sheng Zhang ◽  
Weili Chen ◽  
Huan Tang ◽  
Quan Han ◽  
Shenqiang Yan ◽  
...  

2014 ◽  
Vol 6 (Suppl 1) ◽  
pp. A39.2-A40
Author(s):  
A Honarmand ◽  
R Beck ◽  
M Soltanolkotabi ◽  
S Ansari ◽  
A Shaibani ◽  
...  

Medicine ◽  
2021 ◽  
Vol 100 (1) ◽  
pp. e24145
Author(s):  
Megumi Maeda ◽  
Haruhisa Fukuda ◽  
Ryu Matsuo ◽  
Fumi Kiyuna ◽  
Tetsuro Ago ◽  
...  

2021 ◽  
Vol 84 (1) ◽  
pp. 1662-1666
Author(s):  
Mahmoud Ahmed Shahin ◽  
Mostafa Saleh Melake ◽  
Saad Soliman Ibrahim ◽  
Amira Mohiey El-deen Hamdey

Sign in / Sign up

Export Citation Format

Share Document